BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li M, Zha X, Wang S. The role of N6-methyladenosine mRNA in the tumor microenvironment. Biochim Biophys Acta Rev Cancer 2021;1875:188522. [PMID: 33545295 DOI: 10.1016/j.bbcan.2021.188522] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Luo N. Editorial: Tumor microenvironment in cancer hallmarks and therapeutics. Front Mol Biosci 2022;9:1019830. [DOI: 10.3389/fmolb.2022.1019830] [Reference Citation Analysis]
2 Wang X, Xu D, Chen B, Huang D, Li Z, Sui Y, Lin F, Yao H, Li HY, Lin X, Li T. Delicaflavone Represses Lung Cancer Growth by Activating Antitumor Immune Response through N6-Methyladenosine Transferases and Oxidative Stress. Oxidative Medicine and Cellular Longevity 2022;2022:1-16. [DOI: 10.1155/2022/8619275] [Reference Citation Analysis]
3 Ma J, Chen XQ, Xiang ZL. Identification of a Prognostic Transcriptome Signature for Hepatocellular Carcinoma with Lymph Node Metastasis. Oxid Med Cell Longev 2022;2022:7291406. [PMID: 35847584 DOI: 10.1155/2022/7291406] [Reference Citation Analysis]
4 Zhang F, Liu H, Duan M, Wang G, Zhang Z, Wang Y, Qian Y, Yang Z, Jiang X. Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application. J Hematol Oncol 2022;15. [DOI: 10.1186/s13045-022-01304-5] [Reference Citation Analysis]
5 Guo Y, Bai Y, Wang L, Xu Z, Wang X, Wang W. The significance of m6A RNA methylation modification in prognosis and tumor microenvironment immune infiltration of cervical cancer. Medicine (Baltimore) 2022;101:e29818. [PMID: 35777046 DOI: 10.1097/MD.0000000000029818] [Reference Citation Analysis]
6 Qu X, Zhang Y, Sang X, Ren D, Zhao H, Wong STC. Methyladenosine Modification in RNAs: From Regulatory Roles to Therapeutic Implications in Cancer. Cancers 2022;14:3195. [DOI: 10.3390/cancers14133195] [Reference Citation Analysis]
7 Chen F, Xie X, Chao M, Cao H, Wang L. The Potential Value of m6A RNA Methylation in the Development of Cancers Focus on Malignant Glioma. Front Immunol 2022;13:917153. [DOI: 10.3389/fimmu.2022.917153] [Reference Citation Analysis]
8 Sun H, Huang B, Cao J, Yan Q, Yin M. Editorial: Epigenetic Regulation and Tumor Immunotherapy. Front Oncol 2022;12:893157. [PMID: 35600405 DOI: 10.3389/fonc.2022.893157] [Reference Citation Analysis]
9 Gao Y, Wang H, Chen S, An R, Chu Y, Li G, Wang Y, Xie X, Zhang J. Single-cell N6-methyladenosine regulator patterns guide intercellular communication of tumor microenvironment that contribute to colorectal cancer progression and immunotherapy. J Transl Med 2022;20:197. [PMID: 35509079 DOI: 10.1186/s12967-022-03395-7] [Reference Citation Analysis]
10 Zhou H, Mao L, Xu H, Wang S, Tian J. The functional roles of m6A modification in T lymphocyte responses and autoimmune diseases. Cytokine Growth Factor Rev 2022;65:51-60. [PMID: 35490098 DOI: 10.1016/j.cytogfr.2022.04.004] [Reference Citation Analysis]
11 Zhao W, Li J, Ma Q, Cai J, Li A, Wu W, Lv Y, Cai M. N6-methyladenosine modification participates in neoplastic immunoregulation and tumorigenesis. J Cell Physiol 2022. [PMID: 35342948 DOI: 10.1002/jcp.30730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zheng B, Cheng F, Yao Z, Zhang Y, Cong Z, Wang J, Niu Z, He W. Identification of New m6A Methylation Modification Patterns and Tumor Microenvironment Infiltration Landscape that Predict Clinical Outcomes for Papillary Renal Cell Carcinoma Patients. Front Cell Dev Biol 2022;10:818194. [DOI: 10.3389/fcell.2022.818194] [Reference Citation Analysis]
13 Li X, Ma S, Deng Y, Yi P, Yu J. Targeting the RNA m6A modification for cancer immunotherapy. Mol Cancer 2022;21:76. [PMID: 35296338 DOI: 10.1186/s12943-022-01558-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Liu Q. Current Advances in N6-Methyladenosine Methylation Modification During Bladder Cancer. Front Genet 2021;12:825109. [PMID: 35087575 DOI: 10.3389/fgene.2021.825109] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
15 Li J, Cao J, Liang C, Deng R, Li P, Tian J. The analysis of N6-methyladenosine regulators impacting the immune infiltration in clear cell renal cell carcinoma. Med Oncol 2022;39:41. [PMID: 35092501 DOI: 10.1007/s12032-021-01645-0] [Reference Citation Analysis]
16 Liu Y, Li G, Yang Y, Lu Z, Wang T, Wang X, Liu J. Analysis of N6-Methyladenosine Modification Patterns and Tumor Immune Microenvironment in Pancreatic Adenocarcinoma. Front Genet 2021;12:752025. [PMID: 35046996 DOI: 10.3389/fgene.2021.752025] [Reference Citation Analysis]
17 Zhang H, Kong W, Zhao X, Han C, Liu T, Li J, Song D. N6-Methyladenosine-Related lncRNAs as potential biomarkers for predicting prognoses and immune responses in patients with cervical cancer. BMC Genom Data 2022;23:8. [PMID: 35042477 DOI: 10.1186/s12863-022-01024-2] [Reference Citation Analysis]
18 Guo L, Yang H, Zhou C, Shi Y, Huang L, Zhang J. N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy. Front Immunol 2021;12:773570. [PMID: 34956201 DOI: 10.3389/fimmu.2021.773570] [Reference Citation Analysis]
19 Wang E, Li Y, Ming R, Wei J, Du P, Zhou P, Zong S, Xiao H. The Prognostic Value and Immune Landscapes of a m6A/m5C/m1A-Related LncRNAs Signature in Head and Neck Squamous Cell Carcinoma. Front Cell Dev Biol 2021;9:718974. [PMID: 34917609 DOI: 10.3389/fcell.2021.718974] [Reference Citation Analysis]
20 Li D, Liang J, Cheng C, Guo W, Li S, Song W, Song Z, Bai Y, Zhang Y, Wu X, Zhang W. Identification of m6A-Related lncRNAs Associated With Prognoses and Immune Responses in Acute Myeloid Leukemia. Front Cell Dev Biol 2021;9:770451. [PMID: 34869365 DOI: 10.3389/fcell.2021.770451] [Reference Citation Analysis]
21 Peng H, Ding X, Xu J, Han Y, Yang J, Tang X, Wang S, Liu Y. Elevated Expression of the Long Noncoding RNA MAFTRR in Patients with Hashimoto's Thyroiditis. J Immunol Res 2021;2021:3577011. [PMID: 34869781 DOI: 10.1155/2021/3577011] [Reference Citation Analysis]
22 Xie J, Huang Z, Jiang P, Wu R, Jiang H, Luo C, Hong H, Yin H. Elevated N6-Methyladenosine RNA Levels in Peripheral Blood Immune Cells: A Novel Predictive Biomarker and Therapeutic Target for Colorectal Cancer. Front Immunol 2021;12:760747. [PMID: 34659267 DOI: 10.3389/fimmu.2021.760747] [Reference Citation Analysis]
23 Huang Y, Yang Z, Huang C, Jiang X, Yan Y, Zhuang K, Wen Y, Liu F, Li P. Identification of N6-Methylandenosine-Related lncRNAs for Subtype Identification and Risk Stratification in Gastric Adenocarcinoma. Front Oncol 2021;11:725181. [PMID: 34646770 DOI: 10.3389/fonc.2021.725181] [Reference Citation Analysis]
24 Zhu H, Jia X, Wang Y, Song Z, Wang N, Yang Y, Shi X. M6A Classification Combined With Tumor Microenvironment Immune Characteristics Analysis of Bladder Cancer. Front Oncol 2021;11:714267. [PMID: 34604051 DOI: 10.3389/fonc.2021.714267] [Reference Citation Analysis]
25 Cai Z, Zhang J, Liu Z, Su J, Xu J, Li Z, Meng H, Zhang H, Huang M, Zhao D, Duan C, He X. Identification of an N6-methyladenosine (m6A)-related signature associated with clinical prognosis, immune response, and chemotherapy in primary glioblastomas. Ann Transl Med 2021;9:1241. [PMID: 34532378 DOI: 10.21037/atm-21-3139] [Reference Citation Analysis]
26 Xiao Y, Zhou H, Jiang L, Liu R, Chen Q. Epigenetic regulation of ion channels in the sense of taste. Pharmacol Res 2021;172:105760. [PMID: 34450315 DOI: 10.1016/j.phrs.2021.105760] [Reference Citation Analysis]
27 Li J, Wang W, Zhou Y, Liu L, Zhang G, Guan K, Cui X, Liu X, Huang M, Cui G, Sun R. m6A Regulator-Associated Modification Patterns and Immune Infiltration of the Tumor Microenvironment in Hepatocarcinoma. Front Cell Dev Biol 2021;9:687756. [PMID: 34277630 DOI: 10.3389/fcell.2021.687756] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
28 Cui Y, Cai J, Wang W, Wang S. Regulatory Effects of Histone Deacetylase Inhibitors on Myeloid-Derived Suppressor Cells. Front Immunol 2021;12:690207. [DOI: 10.3389/fimmu.2021.690207] [Reference Citation Analysis]
29 Song G, Zhang Y, Tian J, Ma J, Yin K, Xu H, Wang S. TRAF6 Regulates the Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Tumor-Bearing Host. Front Immunol 2021;12:649020. [PMID: 33717204 DOI: 10.3389/fimmu.2021.649020] [Reference Citation Analysis]